Sp17 recombinant protein-primed CTLs could lyse autologous tumor cells expressing Sp17.

Tumor cell cytotoxicity by CTLs could be blocked by a monoclonal antibody directed at monomorphic HLA class I molecules but not HLA class II molecules (patients 1-3 were Sp17⁺ and patient 4 Sp17⁻; E/T ratio, 20:1). Results are expressed as mean ± SD.